Drug Trial Radar · NCT01469377
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Last checked: Nov 19, 2026Latest source record: May 1, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
819
Actual
Start
Dec 15, 2011
Primary completion
Dec 12, 2013
Study completion Dec 12, 2013
Sponsor
- Lead sponsor
- Forest LaboratoriesAbbVie (ABBV)
- Sponsor type
- Industry
- Collaborators
- Gedeon Richter Ltd.
- First posted
- Nov 10, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An outpatient study to evaluate the safety and efficacy of cariprazine as adjunct to antidepressant therapy (ADT) in participants with major depressive disorder (MDD) who have an inadequate response to ADT alone. This clinical study compared cariprazine + ADT with placebo + ADT in outpatients with a diagnosis of MDD and an inadequate response to ADT. The study consisted of approximately 2 weeks of screening and washout followed by 8 weeks of double-blind treatment followed by a 1 week safety follow-up.
Conditions
- Major Depressive Disorder
Interventions
PlaceboDrug
Placebo was supplied in capsules
CariprazineDrug
Cariprazine was supplied in capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 8Time frame: Baseline to Week 8
Locations
72 sites in 6 countries. Site status is shown where the registry gives one.
Forest Investigative Site 077
Garden Grove, California
Forest Investigative Site 019
National City, California
Forest Investigative Site 039
Oceanside, California
Forest Investigative Site 015
Orange, California
Forest Investigative Site 050
Orange, California
Forest Investigative Site 008
Redlands, California
Forest Investigative Site 066
Sherman Oaks, California
Forest Investigative Site 063
Gainesville, Florida
Forest Investigative Site 029
Jacksonville, Florida
Forest Investigative Site 012
Kissimmee, Florida
Forest Investigative Site 023
Miami, Florida
Forest Investigative Site 026
Orlando, Florida
Forest Investigative Site 062
Atlanta, Georgia
Forest Investigative Site 065
Smyrna, Georgia
Forest Investigative Site 074
Prairie Village, Kansas
Forest Investigative Site 040
Flowood, Mississippi
Forest Investigative Site 068
Creve Coeur, Missouri
Forest Investigative Site 061
Cherry Hill, New Jersey
Forest Investigative Site 038
Marlton, New Jersey
Forest Investigative Site 030
Albuquerque, New Mexico
Forest Investigative Site 076
Brooklyn, New York
Forest Investigative Site 037
Mount Kisco, New York
Forest Investigative Site 067
New York, New York
Forest Investigative Site 049
New York, New York
Forest Investigative Site 047
Canton, Ohio
Forest Investigative Site 021
Dayton, Ohio
Forest Investigative Site 022
Portland, Oregon
Forest Investigative Site 027
Salem, Oregon
Forest Investigative Site 069
Bridgeville, Pennsylvania
Forest Investigative Site 025
Philadelphia, Pennsylvania
Forest Investigative Site 031
Reading, Pennsylvania
Forest Investigative Site 048
Memphis, Tennessee
Forest Investigative Site 024
Austin, Texas
Forest Investigative Site 020
Dallas, Texas
Forest Investigative Site 070
Houston, Texas
Forest Investigative Site 080
San Antonio, Texas
Forest Investigative Site 028
Salt Lake City, Utah
Forest Investigative Site 032
Bellevue, Washington
Forest Investigative Site 034
Kirkland, Washington
Forest Investigative Site 203
Tallinn, Estonia
Showing 40 of 72 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.